[et_pb_section bb_built=”1″ admin_label=”section”][et_pb_row admin_label=”row” background_position=”top_left” background_repeat=”repeat” background_size=”initial”][et_pb_column type=”4_4″][et_pb_text use_border_color=”off” border_color=”#ffffff” border_style=”solid” background_position=”top_left” background_repeat=”repeat” background_size=”initial” _builder_version=”3.3.1″]<\/p>\n
Adriana Schwartz<\/em><\/p>\n <\/p>\n Throughout 2020 we witness the desperate race of pharmaceutical companies in search of the \u201cHoly Grail\u201d of the vaccine that would eliminate the pandemic unleashed by COVID-19. Scientific career in which pharmaceutical companies sought both to continue climbing the ladder of scientific prestige, and to obtain exorbitant profits with the discovery of the appropriate vaccine to defeat COVID-19.<\/p>\n The result of the economic, investigative, obtaining legal authorizations race, and intriguing geopolitical games, has already yielded concrete results.<\/p>\n At least 73 research projects to discover vaccines against COVID-19 have been launched in a very few countries in the world with research capacity in health. Out of the 73 projects, so far, only nine have received authorization to be commercialized, in at least one country<\/p>\n<\/h3>\n
Abstract<\/strong><\/h3>\n